Epigenome dysregulation in cholangiocarcinoma

Research output: Contribution to journal › Review › Research › peer-review

Standard

Epigenome dysregulation in cholangiocarcinoma. / O'Rourke, Colm J; Munoz-Garrido, Patricia; Aguayo, Esmeralda L; Andersen, Jesper B.

In: BBA Molecular Basis of Disease, Vol. 1864, No. 4, Part B, 2018, p. 1423-1434.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

O'Rourke, CJ, Munoz-Garrido, P, Aguayo, EL & Andersen, JB 2018, 'Epigenome dysregulation in cholangiocarcinoma', BBA Molecular Basis of Disease, vol. 1864, no. 4, Part B, pp. 1423-1434. https://doi.org/10.1016/j.bbadis.2017.06.014

APA

O'Rourke, C. J., Munoz-Garrido, P., Aguayo, E. L., & Andersen, J. B. (2018). Epigenome dysregulation in cholangiocarcinoma. BBA Molecular Basis of Disease, 1864(4, Part B), 1423-1434. https://doi.org/10.1016/j.bbadis.2017.06.014

Vancouver

O'Rourke CJ, Munoz-Garrido P, Aguayo EL, Andersen JB. Epigenome dysregulation in cholangiocarcinoma. BBA Molecular Basis of Disease. 2018;1864(4, Part B):1423-1434. https://doi.org/10.1016/j.bbadis.2017.06.014

Author

O'Rourke, Colm J ; Munoz-Garrido, Patricia ; Aguayo, Esmeralda L ; Andersen, Jesper B. / Epigenome dysregulation in cholangiocarcinoma. In: BBA Molecular Basis of Disease. 2018 ; Vol. 1864, No. 4, Part B. pp. 1423-1434.

Bibtex

@article{81b1a1f0edb64ef4b1df997535688b9c,
title = "Epigenome dysregulation in cholangiocarcinoma",
abstract = "Epigenomics is a fast-evolving field of research that has lately attracted considerable interest, mainly due to the reversibility of epigenetic marks. Clinically, among solid tumors, the field is still limited. In cholangiocarcinoma (CCA) it is well known that the epigenetic landscape is deregulated both during carcinogenesis and disease progression as a consequence of aberrant mechanisms leading to genome instability. In this article, we will briefly review the molecular alterations that have been described in the transformation of normal cholangiocytes into malignant derivatives, focusing on the role of non-coding RNA (ncRNA) interactions, DNA methylation, post-translational modifications (PTMs) of histones and chromatin remodeling complexes.",
keywords = "Journal Article, Review",
author = "O'Rourke, {Colm J} and Patricia Munoz-Garrido and Aguayo, {Esmeralda L} and Andersen, {Jesper B}",
note = "Copyright {\textcopyright} 2017 Elsevier B.V. All rights reserved.",
year = "2018",
doi = "10.1016/j.bbadis.2017.06.014",
language = "English",
volume = "1864",
pages = "1423--1434",
journal = "B B A - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "4, Part B",

}

RIS

TY - JOUR

T1 - Epigenome dysregulation in cholangiocarcinoma

AU - O'Rourke, Colm J

AU - Munoz-Garrido, Patricia

AU - Aguayo, Esmeralda L

AU - Andersen, Jesper B

N1 - Copyright © 2017 Elsevier B.V. All rights reserved.

PY - 2018

Y1 - 2018

N2 - Epigenomics is a fast-evolving field of research that has lately attracted considerable interest, mainly due to the reversibility of epigenetic marks. Clinically, among solid tumors, the field is still limited. In cholangiocarcinoma (CCA) it is well known that the epigenetic landscape is deregulated both during carcinogenesis and disease progression as a consequence of aberrant mechanisms leading to genome instability. In this article, we will briefly review the molecular alterations that have been described in the transformation of normal cholangiocytes into malignant derivatives, focusing on the role of non-coding RNA (ncRNA) interactions, DNA methylation, post-translational modifications (PTMs) of histones and chromatin remodeling complexes.

AB - Epigenomics is a fast-evolving field of research that has lately attracted considerable interest, mainly due to the reversibility of epigenetic marks. Clinically, among solid tumors, the field is still limited. In cholangiocarcinoma (CCA) it is well known that the epigenetic landscape is deregulated both during carcinogenesis and disease progression as a consequence of aberrant mechanisms leading to genome instability. In this article, we will briefly review the molecular alterations that have been described in the transformation of normal cholangiocytes into malignant derivatives, focusing on the role of non-coding RNA (ncRNA) interactions, DNA methylation, post-translational modifications (PTMs) of histones and chromatin remodeling complexes.

KW - Journal Article

KW - Review

U2 - 10.1016/j.bbadis.2017.06.014

DO - 10.1016/j.bbadis.2017.06.014

M3 - Review

C2 - 28645654

VL - 1864

SP - 1423

EP - 1434

JO - B B A - Molecular Basis of Disease

JF - B B A - Molecular Basis of Disease

SN - 0925-4439

IS - 4, Part B

ER -

ID: 182354750